John D. Diekman
Director/Board Member at ZAI LAB LIMITED
Net worth: 1 M $ as of 2024-03-30
Profile
John D.
Diekman was the founder of Bay City Capital LLC (founded in 1998) and 5AM Venture Management LLC (founded in 2002) where he held the titles of Managing Director and Founding Partner, respectively.
He currently holds director positions at Wildcat Discovery Technologies, Inc., Cleave Therapeutics, Inc., and Calibrium LLC, and is an Independent Director at Zai Lab Ltd.
He also serves as a Trustee at Princeton University.
Dr. Diekman previously held chairman positions at The Scripps Research Institute, Affymax NV, Ambrx, Inc., and Envoy Therapeutics, Inc. He was also the Chairman of IDEAYA Biosciences, Inc. from 2015 to 2020.
Additionally, he held director positions at LJL Biosystems, Inc., Ventro Corp., Kalypsys, Inc., Phenomix Corp., GenoSpectra, Inc., Ingenuity Systems, Inc., Antipodean Pharmaceuticals, Inc., Marcadia Biotech, Inc., Igenica Biotherapeutics, Inc., Bio*One Capital Pte Ltd., S*BIO Pte Ltd., PhaseRx, Inc., and Cellular Research, Inc. Dr. Diekman received his undergraduate degree from Princeton University in 1965 and his doctorate from Stanford University in 1969.
He also received a doctorate from Monash University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ZAI LAB LTD.
0.07% | 2023-06-29 | 676,850 ( 0.07% ) | 1 M $ | 2024-03-30 |
John D. Diekman active positions
| Companies | Position | Start |
|---|---|---|
| ZAI LAB LIMITED | Director/Board Member | 2016-12-31 |
5AM Venture Management LLC
 5AM Venture Management LLC Investment ManagersFinance 5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US. | Founder | 2001-12-31 |
| Princeton University | Director/Board Member | - |
Calibrium LLC
 Calibrium LLC Pharmaceuticals: MajorHealth Technology Calibrium LLC develops biopharmaceuticals and diabetic drugs. The company is a biotech company that develops novel peptides that helps in the treatment of diabetes and related metabolic diseases. The company was founded by Fritz French and Richard DiMarch in 2013 and is headquartered in Carmel, IN. | Director/Board Member | - |
Wildcat Discovery Technologies, Inc.
 Wildcat Discovery Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Wildcat Discovery Technologies, Inc. provides commercial research and development services. The firm engages in development projects for materials for other applications, including gas storage, carbon capture, thermoelectric, and structural materials. Its products include electrolyte additives such as EM1, CM1, CM2, and EM2. The company was founded by Peter G. Schultz and Robert K. Downs in 2006 and is headquartered in San Diego, CA. | Director/Board Member | - |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Director/Board Member | - |
Former positions of John D. Diekman
| Companies | Position | End |
|---|---|---|
| IDEAYA BIOSCIENCES, INC. | Chairman | 2020-05-31 |
| AFFYMETRIX, INC. | Director/Board Member | 2013-05-06 |
Phenomix Corp.
 Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Director/Board Member | 2010-10-27 |
| ░░░ ░░░░ ░░░░░░░ ░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Training of John D. Diekman
| Stanford University | Doctorate Degree |
| Monash University | Doctorate Degree |
| Princeton University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| PHASERX, INC. | Health Technology |
| IDEAYA BIOSCIENCES, INC. | Health Technology |
| ZAI LAB LIMITED | Health Technology |
| Private companies | 21 |
|---|---|
Affymetrix, Inc.
 Affymetrix, Inc. Medical SpecialtiesHealth Technology Affymetrix, Inc. develops, manufactures and sells products and services for genetic analysis. The company was founded by Stephen P. A. Fodor in 1992 and is headquartered in Santa Clara, CA. | Health Technology |
LJL Biosystems, Inc.
 LJL Biosystems, Inc. Medical DistributorsDistribution Services LJL BioSystems, Inc. develops, designs, produces and sells infrastructure tools for drug discovery. Its products are used in the discovery process of screening and genotyping. It serves pharmaceutical, biotechnology and genomics companies as well as research institutions. The company is located in Sunnyvale, CA. | Distribution Services |
Ventro Corp.
 Ventro Corp. Information Technology ServicesTechnology Services Ventro Corp. provides e-commerce solutions. | Technology Services |
Kalypsys, Inc.
 Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | Health Technology |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
GenoSpectra, Inc.
 GenoSpectra, Inc. BiotechnologyHealth Technology Genospectra, Inc. was a life science company developing technologies and products for Parallel Quantitative Biology (PQB). Genospectra's PQB initiative was focused on creating novel cell-based assays and tools that enable multiplex measurements of molecular events, such as intracellular pathway analysis, in a quantitative and scalable manner. Genospectra's first product line, the QuantiGene Reagent System was launched in 2003, and was powered by the FDA approved and proprietary branched DNA technology for gene expression analysis in cell-based assays. Genospectra was headquartered in Fremont, CA. | Health Technology |
Ingenuity Systems, Inc.
 Ingenuity Systems, Inc. Information Technology ServicesTechnology Services Ingenuity Systems, Inc. provides intuitive web-based applications for quickly analyzing and accurately interpreting the biological meaning of genomics data. The company was founded in 1998 and is headquartered in Redwood City, CA. | Technology Services |
Antipodean Pharmaceuticals, Inc.
 Antipodean Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Antipodean Pharmaceuticals, Inc. manufactures pharmaceutical products and provides pre clinical services. Its product MitoQ, which blocks mitochondrial oxidative damage and prevents cell death. The company was founded in 2002 and is headquartered in Menlo Park, CA. | Health Technology |
Wildcat Discovery Technologies, Inc.
Wildcat Discovery Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Wildcat Discovery Technologies, Inc. provides commercial research and development services. The firm engages in development projects for materials for other applications, including gas storage, carbon capture, thermoelectric, and structural materials. Its products include electrolyte additives such as EM1, CM1, CM2, and EM2. The company was founded by Peter G. Schultz and Robert K. Downs in 2006 and is headquartered in San Diego, CA. | Commercial Services |
Marcadia Biotech, Inc.
 Marcadia Biotech, Inc. Pharmaceuticals: MajorHealth Technology Marcadia Biotech, Inc. develops therapeutic products for diabetes and obesity. It is a biopharmaceutical company focuses on developing a broad portfolio of drug candidates for treatment of diabetes and obesity. The company was founded in 2005 and is headquartered in Carmel, IN. | Health Technology |
Igenica Biotherapeutics, Inc.
 Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Health Technology |
Calibrium LLC
Calibrium LLC Pharmaceuticals: MajorHealth Technology Calibrium LLC develops biopharmaceuticals and diabetic drugs. The company is a biotech company that develops novel peptides that helps in the treatment of diabetes and related metabolic diseases. The company was founded by Fritz French and Richard DiMarch in 2013 and is headquartered in Carmel, IN. | Health Technology |
| Affymax NV | Health Technology |
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Bay City Capital LLC
 Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in San Rafael, California. | Finance |
Bio*One Capital Pte Ltd.
 Bio*One Capital Pte Ltd. Investment ManagersFinance Bio*One Capital Pte Ltd (Bio*One Capital) is a venture capital subsidiary of EDB Investments Pte Ltd founded in 1991. The firm is headquartered in Singapore. | Finance |
5AM Venture Management LLC
5AM Venture Management LLC Investment ManagersFinance 5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US. | Finance |
S*BIO Pte Ltd.
 S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Health Technology |
Envoy Therapeutics, Inc.
 Envoy Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Envoy Therapeutics, Inc. manufactures and develops therapeutic drugs for neurological and psychiatric diseases. It was founded in 2009 and is headquartered in Jupiter, FL. | Health Technology |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Health Technology |
Cellular Research, Inc.
 Cellular Research, Inc. BiotechnologyHealth Technology Cellular Research, Inc. operates as a biotechnology research and development company. It offer Precise assays that provides quantitation of mRNA targets in single cells and small samples; precise predefined gene expression panels; and Pixel system, a detection platform for direct mRNA quantitation from single cells and rare samples. The company’s products are used in various applications that include gene expression validation, RNA-seq validation, pathway validation, and rare transcript detection. The company was founded by Stephen P. A. Fodor, Ari Chaney, Stephen R. Quake and Glenn Fu in 2011 and is headquartered in Menlo Park, CA. | Health Technology |
- Stock Market
- Insiders
- John D. Diekman
